The University of Southampton
University of Southampton Institutional Repository

Role of protein kinase B in breast cancer

Role of protein kinase B in breast cancer
Role of protein kinase B in breast cancer
Breast cancer is the most common cancer in women and is increasing in both the developed and developing countries. There is an urgent need to understand the precise mechanisms of tumour development in breast cancer, to develop new treatment strategies and to identify predictive markers for tumour aggressiveness and therapy resistance.
A protein called protein kinase B (PKB, also called Akt) is frequently elevated in breast cancers and has been implicated as a key player in breast cancer development and progression. The activation level of PKB is also thought to correlate with patient outcome. However, the function of the three isoforms of PKB in mediating the crucial responses is unknown. We have developed a set of antisense phosphorothioate oligonucleotide probes that target antisense-active regions in PKB and that enable >90% knockdown of all three known PKB isoforms (alpha, beta and gamma), either individually or in various combinations, including removal of all three isoforms together. We have demonstrated that these agents specifically and potently prevent the growth of breast cancer cells. Application of these antisense agents offers a unique opportunity to understand how PKB works and contributes to breast cancer, and to provide insight into the role of signalling by individual PKB isoforms in breast cancer cells. Such work may also identify clinically relevant markers of disease, thereby enabling better predictors of patient outcome, and provide the necessary intellectual framework for the development of PKB-isoform selective inhibitors (for example, antisense oligonucleotides, small chemical inhibitors) as novel therapeutic agents.
1465-5411
23
Sale, E.M.
6cb82c59-6168-403d-8703-7000728c8584
Hodgkinson, C.P.
d7d2d1d8-5e1f-4074-a60b-14c38fdc6ad0
Jones, N.P.
3d1aabaf-6b32-4685-a026-da35ee9f56b5
Sale, G.J.
9da2ccd1-1a75-42e8-8c55-5bdfef6ccd10
Sale, E.M.
6cb82c59-6168-403d-8703-7000728c8584
Hodgkinson, C.P.
d7d2d1d8-5e1f-4074-a60b-14c38fdc6ad0
Jones, N.P.
3d1aabaf-6b32-4685-a026-da35ee9f56b5
Sale, G.J.
9da2ccd1-1a75-42e8-8c55-5bdfef6ccd10

Sale, E.M., Hodgkinson, C.P., Jones, N.P. and Sale, G.J. (2006) Role of protein kinase B in breast cancer. Breast Cancer Research, 8 (2), 23. (doi:10.1186/bcr1578).

Record type: Article

Abstract

Breast cancer is the most common cancer in women and is increasing in both the developed and developing countries. There is an urgent need to understand the precise mechanisms of tumour development in breast cancer, to develop new treatment strategies and to identify predictive markers for tumour aggressiveness and therapy resistance.
A protein called protein kinase B (PKB, also called Akt) is frequently elevated in breast cancers and has been implicated as a key player in breast cancer development and progression. The activation level of PKB is also thought to correlate with patient outcome. However, the function of the three isoforms of PKB in mediating the crucial responses is unknown. We have developed a set of antisense phosphorothioate oligonucleotide probes that target antisense-active regions in PKB and that enable >90% knockdown of all three known PKB isoforms (alpha, beta and gamma), either individually or in various combinations, including removal of all three isoforms together. We have demonstrated that these agents specifically and potently prevent the growth of breast cancer cells. Application of these antisense agents offers a unique opportunity to understand how PKB works and contributes to breast cancer, and to provide insight into the role of signalling by individual PKB isoforms in breast cancer cells. Such work may also identify clinically relevant markers of disease, thereby enabling better predictors of patient outcome, and provide the necessary intellectual framework for the development of PKB-isoform selective inhibitors (for example, antisense oligonucleotides, small chemical inhibitors) as novel therapeutic agents.

This record has no associated files available for download.

More information

Published date: 1 January 2006

Identifiers

Local EPrints ID: 56611
URI: http://eprints.soton.ac.uk/id/eprint/56611
ISSN: 1465-5411
PURE UUID: b6846234-b423-45d8-a836-248d9d8048c8

Catalogue record

Date deposited: 06 Aug 2008
Last modified: 15 Mar 2024 11:02

Export record

Altmetrics

Contributors

Author: E.M. Sale
Author: C.P. Hodgkinson
Author: N.P. Jones
Author: G.J. Sale

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×